Navigation Links
New Cardiovascular Biomarker Available for Scientist in North America
Date:9/24/2009

SALEM, New Hampshire, and STOCKHOLM, September 24 /PRNewswire/ -- Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), and ALPCO, a company providing high quality research immunoassays, announced today that they have signed a distribution agreement.

Sean Conley, COO of ALPCO, said "We are very excited about the opportunities presented by this agreement, which will enable us to offer a new CVD biomarker to customers in North America. CVDefine(R) may add important and independent information in cardiovascular risk assessment and we believe there is a lot of interest from scientist in the field to use this to generate further clinical research data".

High levels of IgM antibodies against phosphorylcholine (anti-PC) have been shown to be predictive of less atherosclerosis development in hypertensive patients after a five-year follow up. However, in 2008 data indicating that low anti-PC levels predict an increased risk of CVD were presented. One study included myocardial infarction (MI) patients and suggested that anti-PC measurements could be used to predict the likelihood of secondary CVD events up to six months after an initial event. This has since been followed up with another study involving over 1000 ACS patients. The product, CVDefine, was introduced last year and provides an easy-to-use ELISA kit (Research Use Only) for quantitative analysis of anti-PC in human blood. A CVDefine CE-marked kit is available in Europe.

"This distribution agreement is another important step for Athera as we expand in the North American market. This agreement broadens our presence and increases the exposure of our trademark. I am pleased with the opportunities this represents and I look forward to working with the efficient and experienced team from ALPCO", says Carina Schmidt, CEO Athera Biotechnologies AB.

About Athera Biotechnologies

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is a Karolinska Development AB (publ) portfolio company and is also a major partner in the highly ranked EU-project CVDIMMUNE, which also includes Karolinska Institute, Imperial College London, Phadia GmbH and TNO.

http://www.athera.se

About ALPCO

ALPCO (American Laboratory Products Company) was founded in 1990 as an importer and distributor of high quality research immunoassay kits. In recent years, ALPCO has solidified its place in the market not only as a distributor but as a developer and manufacturer of immunoassays. Much of this successful growth can be attributed to the ongoing communication and collaborative relationships with customers and respected thought leaders in the academic, biotech and clinical arenas.

   http://www.alpco.com

    Contact:

    Dan Keefe
    Director of Marketing
    Phone: +1-603-893-8914
    Mail: dkeefe@alpco.com

    Carina Schmidt
    CEO
    Phone: +46-70-552-5115
    Mail: c.schmidt@athera.se


'/>"/>
SOURCE Athera Biotechnologies & ALPCO
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
2. CRESTOR(R) Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter
3. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
4. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
5. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
6. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
7. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
8. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
9. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
10. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
11. Cardiovascular Fitness Not Affected by Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/28/2017)...  Rosen Law Firm, a global investor rights law ... on behalf of purchasers of Kitov Pharmaceutical Holdings Ltd. ... to Kitov,s initial public offering on or about November ... from November 20, 2015 through February 3, 2017, both ... recover damages for Kitov investors under the federal securities ...
(Date:3/28/2017)... Summary GBI ... a Key Component of Multichannel Marketing" provides a ... in the digital age. While the pharmaceutical ... advancements, it has been much slower to adopt ... traditional channels and methods. However, the decreasing effectiveness ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... An ... braces. "The rubber bands used in conjunction with my braces always rubbed against ... design a way to prevent this problem." The O.B.S. was the result of ...
(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, 2017 , ... ... treatment of a growing number of cancers and is touted to be the next ... of treatment, thus far, has been in the form of immune checkpoint inhibitors such ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (SOGO™), a specialized continuing medical education conference for clinicians who manage some of ... Square, New York. , The program will be led by co- chairs ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 ... the only option for on-premises installation of its Help System for SharePoint was at ... the system into the entire tenant. , The company recently released a modified ...
(Date:3/28/2017)... ... ... getting birth control isn’t as easy as it should be. In fact, millions of women ... care facility or a pharmacy within 60 minutes of where they live. This is especially ... are faced with health or personal issues that leave them homebound. To help facilitate better ...
Breaking Medicine News(10 mins):